膵臓癌（浸潤性膵管癌）に対する術前化学療法とConversion surgery
Saved in:
| Published in | 日本医科大学医学会雑誌 Vol. 20; no. 2; pp. 67 - 72 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
日本医科大学医学会
25.04.2024
|
| Online Access | Get full text |
| ISSN | 1349-8975 1880-2877 |
| DOI | 10.1272/manms.20.67 |
Cover
| Author | 古木, 裕康 中村, 慶春 髙田, 英志 吉岡, 正人 相本, 隆幸 上田, 純志 松谷, 毅 吉田, 寛 谷合, 信彦 水谷, 聡 |
|---|---|
| Author_xml | – sequence: 1 fullname: 中村, 慶春 organization: 日本医科大学千葉北総病院消化器外科 – sequence: 1 fullname: 髙田, 英志 organization: 日本医科大学武蔵小杉病院消化器外科 – sequence: 1 fullname: 谷合, 信彦 organization: 日本医科大学武蔵小杉病院消化器外科 – sequence: 1 fullname: 上田, 純志 organization: 日本医科大学武蔵小杉病院消化器外科 – sequence: 1 fullname: 松谷, 毅 organization: 日本医科大学武蔵小杉病院消化器外科 – sequence: 1 fullname: 相本, 隆幸 organization: 日本医科大学武蔵小杉病院消化器外科 – sequence: 1 fullname: 古木, 裕康 organization: 日本医科大学武蔵小杉病院消化器外科 – sequence: 1 fullname: 吉田, 寛 organization: 日本医科大学消化器外科 – sequence: 1 fullname: 水谷, 聡 organization: 日本医科大学武蔵小杉病院消化器外科 – sequence: 1 fullname: 吉岡, 正人 organization: 日本医科大学武蔵小杉病院消化器外科 |
| BookMark | eNo9kE9LAkEAxYcwSK1TX6AvsDZ_3JnZSxDSPxC62HmZ2Z0xF11jxwJv6aGS7CQFHoWoIKpDCB2qL7Ps6q2vkFl0ee_xe_AOLwcyYTNUAKwiWECY4fWGCBumgGGBsgWQRZxDC3PGMrNMio7FHWYvgZwxAYSUMkqyoDI9G0_PB5Nh_-v9Ih2_pR-36en9DE6eR3PYizuPyctn3BnG3cvpaJD0rpL-TfJ0Nxl209fruPNQaoYnKjK1ZrhmjqOqitrLYFGLulErf54HB9tbldKuVd7f2Sttlq0AMS6sovYc6TCJNLexhkwRYTsK-tJHglEtqUTE0z4XzFfUI0RqpqntQ1xkShJfkDzY-N0NTEtUlXsU1RoiarsiatW8unLnd7gYuvhHKPsvvEMRuYEg34xtd2s |
| ContentType | Journal Article |
| Copyright | 2024 日本医科大学医学会 |
| Copyright_xml | – notice: 2024 日本医科大学医学会 |
| DOI | 10.1272/manms.20.67 |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1880-2877 |
| EndPage | 72 |
| ExternalDocumentID | article_manms_20_2_20_67_article_char_ja |
| GroupedDBID | 123 2WC ALMA_UNASSIGNED_HOLDINGS CS3 JSF KQ8 MOJWN OK1 RJT |
| ID | FETCH-LOGICAL-j178a-4fc9b97b1f852f07e3a59e0dbd1a76fb6b13cfd8a7de6c33bf7f65d0247eb3da3 |
| ISSN | 1349-8975 |
| IngestDate | Wed Sep 03 06:30:18 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 2 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j178a-4fc9b97b1f852f07e3a59e0dbd1a76fb6b13cfd8a7de6c33bf7f65d0247eb3da3 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/manms/20/2/20_67/_article/-char/ja |
| PageCount | 6 |
| ParticipantIDs | jstage_primary_article_manms_20_2_20_67_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2024/04/25 |
| PublicationDateYYYYMMDD | 2024-04-25 |
| PublicationDate_xml | – month: 04 year: 2024 text: 2024/04/25 day: 25 |
| PublicationDecade | 2020 |
| PublicationTitle | 日本医科大学医学会雑誌 |
| PublicationTitleAlternate | 日医大医会誌 |
| PublicationYear | 2024 |
| Publisher | 日本医科大学医学会 |
| Publisher_xml | – name: 日本医科大学医学会 |
| References | 25. Von Hoff DD, Ervin T, Arena FP, et al.: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703 14. Eguchi H, Takeda Y, Takahashi H, et al.: A Prospective, Open―Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full―Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 2019; 26: 4498-4505. 8. Conroy T, Hammel P, Hebber M, et al.: FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018; 379: 2395-2406. 2. 日本膵臓学会膵癌診療ガイドライン改定委員会：膵癌診療ガイドライン 2022年版．2022；金原出版 東京 22. Satoi S, Yamaue H, Kato K, et al.: Role of adjuvant surgery for patients with initially unresectablepancreatic cancer with a long-term favorable responseto non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancret Sci 2013; 20: 590-600. 1. Fortner JG: Regional resection of cancer of the pancreas A new surgical approach. Surgery 1973; 73: 307-320. 24. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825 20. Hammel P, Huguet F, Laethem JL, et al.: Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA 2016; 315: 1844-1853. 23. Yanagimoto H, Satoi S, Yamamoto T, et al.: Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Cancers 2020; 12: 1428. 26. Inoue Y, Oba A, Ono Y, Sato T, Ito H, Takahashi Y: Radical Resection for Locally Advanced Pancreatic Cancers in the Era of New Neoadjuvant Therapy—Arterial Resection, Arterial Divestment and Total Pancreatectomy. Cancers 2021; 13: 1818. 6. Oettle H, Post S, Neuhaus P, et al.: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277. 18. Kunzmann V, Siveke J, Algul H, et al.: Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer （NEOLAP-AIO-PAK-0113）: a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6: 128-138. 21. Ioka T, Furuse J, Fukutomi A, et al.: Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106. JJCO 2020; 51: 235-243. 9. Brierley JD, Gospodarowicz MK,Wittekind C: TNM Classification of Malignant Tumors 8th Edition. 2017; Union for International Cancer Control, John Wiley & Sons New Jersey. 5. Von Hoff DD, Ervin T, Arena FP, et al.: Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703. 13. Ghaneh P, Palmar D, Cicconi S, et al.: Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer （ESPAC5）: a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2023; 8: 157-168. 7. Uesaka K, Boku N, Fukutomi A, et al.: Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase3 open-label. Randomized. Non-inferiority trial （JASPAC01）．Lancet 2016; 388: 248-257. 12. 村上義昭，上村健一郎，近藤 成，中川直哉，岡田健司郎，末田泰二郎：BR膵癌の臨床病理学的特徴とその治療戦略．膵臓 2018; 33: 18-26. 3. Burris HA 3rd, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413. 16. 井上陽介，大庭篤志，小野嘉大ほか：切除可能境界膵頭部癌に対するGEM+nab-パクリタキセルによる術前治療の成績．膵臓 2021; 36: 73-81. 17. Klaiber U, Schnaidt E, Hinz U, et al.: Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer. Annal Surg 2021; 273: 154-162. 19. Wainberg Z, Melsi D, Macarulla T, et al.: NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma （NAPOLI 3）: a randomised, open-label, phase 3 trial. Lancet 2023; 402: 1272-1281. 11. National Comprehensive Cancer network®: NCCN Guidelines Pancreatic Adenocarcinoma Version 1. 2024. 15. Yamaguchi J, Yokoyama Y, Fujii T, et al.: Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy （FOLFIRINOX or GEM/nab-PTX） for Borderline-resectable Pancreatic Cancer （NUPAT-01）. Ann Surg 2022; 275: 1043-1049. 10. 日本膵臓学会：膵癌取り扱い規約 第8版．2023；金原出版 東京 4. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825. |
| References_xml | – reference: 10. 日本膵臓学会：膵癌取り扱い規約 第8版．2023；金原出版 東京． – reference: 16. 井上陽介，大庭篤志，小野嘉大ほか：切除可能境界膵頭部癌に対するGEM+nab-パクリタキセルによる術前治療の成績．膵臓 2021; 36: 73-81. – reference: 4. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825. – reference: 8. Conroy T, Hammel P, Hebber M, et al.: FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018; 379: 2395-2406. – reference: 25. Von Hoff DD, Ervin T, Arena FP, et al.: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703． – reference: 7. Uesaka K, Boku N, Fukutomi A, et al.: Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase3 open-label. Randomized. Non-inferiority trial （JASPAC01）．Lancet 2016; 388: 248-257. – reference: 18. Kunzmann V, Siveke J, Algul H, et al.: Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer （NEOLAP-AIO-PAK-0113）: a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6: 128-138. – reference: 24. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825． – reference: 1. Fortner JG: Regional resection of cancer of the pancreas A new surgical approach. Surgery 1973; 73: 307-320. – reference: 15. Yamaguchi J, Yokoyama Y, Fujii T, et al.: Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy （FOLFIRINOX or GEM/nab-PTX） for Borderline-resectable Pancreatic Cancer （NUPAT-01）. Ann Surg 2022; 275: 1043-1049. – reference: 12. 村上義昭，上村健一郎，近藤 成，中川直哉，岡田健司郎，末田泰二郎：BR膵癌の臨床病理学的特徴とその治療戦略．膵臓 2018; 33: 18-26. – reference: 23. Yanagimoto H, Satoi S, Yamamoto T, et al.: Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Cancers 2020; 12: 1428. – reference: 2. 日本膵臓学会膵癌診療ガイドライン改定委員会：膵癌診療ガイドライン 2022年版．2022；金原出版 東京． – reference: 5. Von Hoff DD, Ervin T, Arena FP, et al.: Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703. – reference: 17. Klaiber U, Schnaidt E, Hinz U, et al.: Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer. Annal Surg 2021; 273: 154-162. – reference: 20. Hammel P, Huguet F, Laethem JL, et al.: Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA 2016; 315: 1844-1853. – reference: 21. Ioka T, Furuse J, Fukutomi A, et al.: Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106. JJCO 2020; 51: 235-243. – reference: 6. Oettle H, Post S, Neuhaus P, et al.: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277. – reference: 9. Brierley JD, Gospodarowicz MK,Wittekind C: TNM Classification of Malignant Tumors 8th Edition. 2017; Union for International Cancer Control, John Wiley & Sons New Jersey. – reference: 11. National Comprehensive Cancer network®: NCCN Guidelines Pancreatic Adenocarcinoma Version 1. 2024. – reference: 14. Eguchi H, Takeda Y, Takahashi H, et al.: A Prospective, Open―Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full―Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 2019; 26: 4498-4505. – reference: 26. Inoue Y, Oba A, Ono Y, Sato T, Ito H, Takahashi Y: Radical Resection for Locally Advanced Pancreatic Cancers in the Era of New Neoadjuvant Therapy—Arterial Resection, Arterial Divestment and Total Pancreatectomy. Cancers 2021; 13: 1818. – reference: 3. Burris HA 3rd, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413. – reference: 22. Satoi S, Yamaue H, Kato K, et al.: Role of adjuvant surgery for patients with initially unresectablepancreatic cancer with a long-term favorable responseto non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancret Sci 2013; 20: 590-600. – reference: 19. Wainberg Z, Melsi D, Macarulla T, et al.: NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma （NAPOLI 3）: a randomised, open-label, phase 3 trial. Lancet 2023; 402: 1272-1281. – reference: 13. Ghaneh P, Palmar D, Cicconi S, et al.: Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer （ESPAC5）: a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2023; 8: 157-168. |
| SSID | ssj0066763 ssib001535903 ssib058493814 ssib053392596 ssib000872022 ssib001163323 ssib002484422 |
| Score | 2.3818395 |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 67 |
| Title | 膵臓癌（浸潤性膵管癌）に対する術前化学療法とConversion surgery |
| URI | https://www.jstage.jst.go.jp/article/manms/20/2/20_67/_article/-char/ja |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 日本医科大学医学会雑誌, 2024/04/25, Vol.20(2), pp.67-72 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1880-2877 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0066763 issn: 1349-8975 databaseCode: KQ8 dateStart: 20050101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV0_b9UwEI9QWVgQCBD_1QFPKCWJ7dgekzRVBQIJqZXYothJhie1IFoWJtoBqChTBVLHSgiQEDCgSgzAl3l6r934Ctw5yXt5LUOpWCy_y-_O53P8fBf5bMe54UnNhV9yV5mCukyLwM3BLXeLXOWskB7V9uD5u_fC-UV2-wHHE2-62SWresY8_WteyXFGFWgwrpgl-w8jOxIKBKjD-EIJIwzlkcaYpJLIkMTcVgRRlKRQKiITks6ROCFSktQC4roySyKGFemRSHTYBYlSEvmH2BVJKTibJIpJykkExLShqPpRQGSMcoAXW-fIImdtJSEqtFzQaNhKDqwalCjeSpYJbny3X-1urhxO0ka8AvW4rSQkShrhcWzVBrG-bYXZHo2aG2FGFIY9UhFJFVGx5QK1I4C1L52FSIRjU7MIgRfQmgsMGFoqPOZjvELDoCVAC-D1arxEm8RWq3iOKDHGS8TEVk3l4eBYPENYVONR1QP6yOiAfEFihr8n5DdfbgK74afO8rZz7b_br7OMUaZcqeo7aWbKmgb_1C7Ex6K79gVeZ44HnYWsviOlcYnqy5UOLbaBwMN7l_LlJTz3fqZlmTi9vJkbmUVlgZcFWIQiax9gcmHWgwjnZADrMl6-cud-N0AQYLlOZjeED3QiAKBcTewjkIyN8RDLKIjvRw43eNsKXFTW-mq4wdum4LT2ajJ4oWe3Ov0C77QHsVq7z9O6ngtnnNNNzDgd1X0565zo5eechf3nu_svtva2N3__eDnc_T78-W747AMQ977sWOJGf-3T4Ouv_tp2f_3V_s7WYOP1YPPt4PP7ve314bc3_bWP44k33Uy8887iXLqQzLvNFSluzxcyd1lllFZC-5XkQeWJkuZclV6hCz8XYaVD7VNTFTIXRRkaSnUlqpAXYCdRalrk9IIztfxwubzoTAvD_coYXxutYFU3smQgwoQ0rww1YX7JEbURskf1OTjZUcf28rE5rzinxhPnqjO1-vhJeQ2CgFV93b4nfwAg8tbN |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E8%86%B5%E8%87%93%E7%99%8C%EF%BC%88%E6%B5%B8%E6%BD%A4%E6%80%A7%E8%86%B5%E7%AE%A1%E7%99%8C%EF%BC%89%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E8%A1%93%E5%89%8D%E5%8C%96%E5%AD%A6%E7%99%82%E6%B3%95%E3%81%A8Conversion+surgery&rft.jtitle=%E6%97%A5%E6%9C%AC%E5%8C%BB%E7%A7%91%E5%A4%A7%E5%AD%A6%E5%8C%BB%E5%AD%A6%E4%BC%9A%E9%9B%91%E8%AA%8C&rft.au=%E4%B8%AD%E6%9D%91%2C+%E6%85%B6%E6%98%A5&rft.au=%E9%AB%99%E7%94%B0%2C+%E8%8B%B1%E5%BF%97&rft.au=%E8%B0%B7%E5%90%88%2C+%E4%BF%A1%E5%BD%A6&rft.au=%E4%B8%8A%E7%94%B0%2C+%E7%B4%94%E5%BF%97&rft.date=2024-04-25&rft.pub=%E6%97%A5%E6%9C%AC%E5%8C%BB%E7%A7%91%E5%A4%A7%E5%AD%A6%E5%8C%BB%E5%AD%A6%E4%BC%9A&rft.issn=1349-8975&rft.eissn=1880-2877&rft.volume=20&rft.issue=2&rft.spage=67&rft.epage=72&rft_id=info:doi/10.1272%2Fmanms.20.67&rft.externalDocID=article_manms_20_2_20_67_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1349-8975&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1349-8975&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1349-8975&client=summon |